Merz Aesthetics Korea to launch FDA-approved Ultherapy PRIME in March

Merz Aesthetics Korea announced Tuesday that it will launch Ultherapy PRIME, its next-generation ultrasound lifting device, in mid-March following regulatory approval in January. 

The device, designed to deliver non-surgical skin tightening, builds on the company’s established Ultherapy technology with faster performance, improved imaging, and a more ergonomic design.

The launch follows Ultherapy PRIME’s introduction in the U.S. last September and its European debut in January. The device is FDA-approved and utilizes micro-focused ultrasound with real-time visualization (MFU-V) technology to precisely target skin layers, stimulating collagen production and lifting effects.

A key upgrade is its proprietary DeepSEE real-time imaging, which enhances ultrasound visualization by nearly doubling the field size and eliminating visual noise. 

With three transducers (1.5mm, 3.0mm, and 4.5mm), the device allows practitioners to tailor treatments based on individual skin thickness and goals. A Merz Aesthetics Korea official said the device enables "hyper-personalized lifting procedures" by providing pre-treatment imaging to assess skin structure and thickness, optimize treatment plans, and ensure precise energy delivery.

Merz Aesthetics first introduced Ultherapy in Korea in 2009. The updated platform is expected to expand its footprint in the non-surgical skin tightening market, offering practitioners enhanced visualization and control in delivering treatments.